ArticleJournal of medical biochemistry2026
Correlation analysis of Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B patients.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the potential therapeutic benefits of autoimmune antibody detection in individuals suffering from chronic hepatitis B. Methods: In the observation group, 102 patients with chronic hepatitis B who were admitted between March 2022 and March 2025 were included. Additionally, the control group consisted of 102 healthy people who were examined throughout the same time period. The two groups' autoimmune antibodies were identified, and patients in the observation group with either positive or negative autoimmune antibodies were compared in terms of liver function, liver fibrosis markers, and cytokine levels. Results: The total positive rate of autoimmune antibodies in the observation group was 26.47%, whereas it was 3.92% in the control group (P<0.05). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were noticeably greater in patients in the observation group with positive autoimmune antibodies than in those with negative antibodies. However, the albumin (ALB) and total protein (TP) levels were much lower in these patients than in patients with negative antibodies. A statistically significant difference was observed (P< 0.05). The levels of type III procollagen (PCIII), hyaluronidase (HA), and laminin (LN) were significantly (P<0.05) greater in individuals with positive autoimmune antibodies than in those with negative antibodies. Patients with positive autoimmune antibodies had considerably higher levels of interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-6 (IL-6) than patients with negative antibodies. Patients who were negative for antibodies had significantly higher levels of interferon-y (IFN-y) (P<0.05). Conclusions: Autoimmune antibodies, which influence liver fibrosis indicators and related cytokines, are present in patients with chronic hepatitis B. The identification of autoimmune antibodies in chronic hepatitis B patients can serve as a guide for evaluating illness and determining patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.